International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
Article Received: *20 May 2023* ***Revised:*** *28 July 2023* ***Accepted:*** *16 August 2023*

Liquid Biopsies in Oncology: Revolutionizing Cancer Diagnosis and Monitoring

Dr. Anand Gudur
Dept. of Oncology,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India Email :anandgudur@gmail.com

Dr.Rashmi Gudur
Dept. of Oncology,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

Dr. Aparna Patange,
Department of Medicine, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra

Dr. Sanjay Thorat,
Department of Medicine,Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra

Dr. V.V. Kanase
Professor Department of General Surgery Krishna Institute of Medical Sciences,Krishna Vishwa Vidyapeeth, Karad, Maharashtra, India

Abstract
Synopsis

Oncology has been transformed by liquid biopsies, which offer non-invasive techniques for cancer detection and tracking. This article examines how circulating tumour cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating microRNAs (miRNAs), and their therapeutic uses might revolutionise cancer therapy. CTCs provide information on tumour heterogeneity and metastatic potential since they are excreted from primary or metastatic tumours. Released by necrotic or apoptotic tumour cells, cfDNA is a genetically altered material that helps track the effectiveness of therapy. EVs, which are made up of microvesicles and exosomes, are capable of carrying cancer biomarkers and transferring biomolecules. Stable in circulation, miRNAs show dysregulation in cancer and are therefore useful indicators for both diagnosis and prognosis.

Clinical uses include tracking illness development, evaluating treatment response, and early identification. Early therapies are made possible by the diagnosis of minimal residual illness by liquid biopsies. Therapeutic decisions are guided by real-time monitoring of treatment response, and dynamic evaluations facilitate the development of individualised treatment plans.

Technical difficulties, problems with standardisation, concerns with cost-effectiveness, and difficulties interpreting data are among the challenges. The development of technology, its incorporation into clinical practice, personalised medicine, the identification of biomarkers, and cooperative efforts to overcome obstacles are the main focuses of future directions.

Keywords: Liquid biopsies, circulating tumor cells, cell-free DNA, extracellular vesicles, microRNAs.

Introduction

Invasive tissue biopsies have historically been the mainstay of cancer diagnosis and surveillance. These biopsies need surgical procedures to collect tumour samples for histopathological investigation. Oncological procedures have undergone a revolutionary change with the introduction of liquid biopsies, which are less invasive methods that allow for dynamic assessment of disease growth and real-time monitoring. Liquid biopsies involve the examination of many biomarkers found in readily available body fluids, including blood, urine, and cerebrospinal fluid. These biomarkers offer a plethora of information indicative of the molecular landscape of the tumour [1].

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
***Article Received:** 20 May 2023 **Revised:** 28 July 2023 **Accepted:** 16 August 2023*

The knowledge that tumours continually release biological material into the circulation, such as circulating tumour cells (CTCs), extracellular vesicles (EVs), cell-free DNA (cfDNA), and circulating microRNAs (miRNAs), is the basis for the use of liquid biopsies in oncology [2]. These biomarkers provide vital information on phenotypic heterogeneity, genetic abnormalities, and epigenetic changes associated with tumours, providing insights into the course of the illness and the efficacy of treatment [3].

Proliferating tumour cells (CTCs) are released into the circulation from both primary and metastatic tumours, and are a characteristic feature of tumour spread. Their counting and molecular characterisation, which represent tumour heterogeneity and metastatic potential, offer important prognostic information [4]. Released by necrotic or apoptotic tumour cells, cell-free DNA (cfDNA) is a genetic material containing tumor-specific changes such as chromosomal rearrangements, point mutations, and copy number variations. Actionable mutations can be found and therapy response can be dynamically monitored thanks to cfDNA analysis [5].

Tumour cells release exosomes and microvesicles, which are extracellular vesicles (EVs) that contain lipids, proteins, and nucleic acids characteristic of the original cell. These vesicles are important for intercellular communication and have attracted attention as potential biomarker carriers for cancer detection and tracking [6]. Stable in circulation, circulating microRNAs (miRNAs) show dysregulation in a variety of malignancies and have potential as non-invasive biomarkers for early diagnosis and prognosis [7].

Liquid biopsies have practical uses throughout the whole spectrum of cancer treatment. One of the biggest benefits is their potential for early cancer diagnosis, which makes it possible to identify minimally residual illness and facilitates prompt therapies, both of which improve patient outcomes [8]. Liquid biopsies also give doctors valuable information into the establishment of resistance mechanisms and the effectiveness of therapy by allowing real-time monitoring of treatment response [9]. These dynamic evaluations support the adjustment of treatment plans, guaranteeing a more successful and individualised approach to cancer care [10].

Although liquid biopsies have great potential, a number of obstacles prevent their widespread clinical implementation. Significant obstacles are presented by technical complexity, such as the requirement for very sensitive detection technologies, variability in sample handling, and standardisation of protocols [11]. Furthermore, coordinated efforts and strong validation studies are needed to address problems with the interpretation of liquid biopsy data and the creation of clinically meaningful criteria for biomarker detection [12].

To sum up, the introduction of liquid biopsies signals a paradigm change in cancer surveillance and diagnosis. In the era of precision oncology, their non-invasiveness and the dynamic and extensive molecular insights they provide make them indispensable tools. For their smooth adoption into standard clinical practice, it is necessary to resolve technological issues and validate their clinical value through thorough research. Liquid biopsies have the potential to completely transform the way cancer is managed by providing prompt, individualised therapies that may have a major influence on patient outcomes.

Section 1: Liquid Biopsies and Biomarkers

Tumour cells in circulation (CTCs)

Given the dynamic nature of cancer, circulating tumour cells (CTCs) are an essential indicator in liquid biopsies. CTCs, which come from primary tumours or metastatic lesions, enter the circulation and provide an insight into how the tumour landscape is changing [1]. Counting them and analysing their molecular makeup has made them into prognostic markers that reveal information about tumour heterogeneity, propensity for metastasis, and response to therapy [2]. Because of the phenotypic variability of CTCs, which is reflective of intratumoral heterogeneity, subclonal populations may be evaluated, which is important for comprehending the evolution of tumours and resistance to therapy [3].

Furthermore, because CTCs are uncommon among billions of blood cells, their separation and analysis pose technological difficulties [4]. The isolation of CTCs has been enhanced by developments in immunomagnetic separation methods and microfluidic technology, which has made their molecular characterisation easier [5]. By finding actionable mutations and tracking their progression over the course of the disease, the analysis of CTCs has potential not only for prognostication but also for guiding therapy decisions [6].

DNA without cells (cfDNA)

Another essential element of liquid biopsies is cell-free DNA (cfDNA), which is extracted from necrotic or apoptotic tumour cells and circulated [7]. A thorough understanding of the tumour genome may be obtained by the

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
Article Received: *20 May 2023* ***Revised:*** *28 July 2023* ***Accepted:*** *16 August 2023*

study of cfDNA, which reflects genetic changes such as point mutations, copy number variations, and chromosomal rearrangements [8]. These changes provide an overview of the tumor's clonal development and heterogeneity by reflecting the genetic landscape of the tumour [9].

Therapy optimisation is aided by the dynamic nature of cfDNA, which enables real-time monitoring of treatment response and the formation of resistance mutations [10]. Crucially, early management and the potential to identify disease recurrence prior to clinical symptoms are made possible by the identification of minimal residual illness using cfDNA screening, which enhances patient outcomes [11]. Nevertheless, difficulties in differentiating between cfDNA originating from tumours and non-neoplastic cfDNA continue to arise, requiring the creation of extremely sensitive and specific detection techniques [12].

EVs, or extracellular vesicles

Exosomes and microvesicles are two examples of extracellular vesicles (EVs) that have drawn interest as biomarker carriers in liquid biopsies [13]. EVs are secreted by a variety of cell types, including tumour cells. They include lipids, proteins, and nucleic acids that are characteristic of the cell that produced them [14]. EVs are good candidates for biomarker development because of their function in intercellular communication and their capacity to move cargo across extended distances while in circulation [15].

Certain proteins or nucleic acids that are carried by EVs may serve as biomarkers for the detection and tracking of malignancy. Moreover, EVs' durability across a range of physiological fluids, such as blood and urine, increases their appeal as non-invasive biomarker sources [16]. Ongoing research is still needed, nevertheless, to standardise EV separation procedures and identify certain EV subpopulations that contain biomarkers unique to individual tumours [17].

MiRNAs (circulating microRNAs)

Small non-coding RNA molecules calledcirculating microRNAs (miRNAs) are present in the bloodstream and have been shown to exhibit dysregulation in a number of cancer forms [18]. miRNAs have become important players in the post-transcriptional control of gene expression and may be useful as biomarkers for the diagnosis, prognosis, and response to therapy of cancer [19]. Their usefulness in liquid biopsy-based diagnostics is highlighted by their stability in physiological fluids and differential expression patterns in cancer patients [20].

Section 2: Liquid Biopsies' Clinical Uses

Early Cancer Detection

The ability of liquid biopsies to identify cancer early is one of its most promising features [1]. There is a window of opportunity for early cancer detection thanks to the detection of circulating tumor-derived biomarkers as cfDNA, EVs, miRNAs, and CTCs [2]. Liquid biopsies' sensitivity and specificity in identifying early-stage malignancies allow for prompt therapies, which have a substantial influence on patient outcomes [3].

Liquid biopsies also provide a non-invasive substitute for conventional screening techniques, opening doors for population-wide cancer screening initiatives [4]. Liquid biopsies allow for the early detection of early-stage malignancies or limited residual illness, which can lead to a reduction in the morbidity and mortality that come with advanced-stage disease [5].

Evaluation of the Response to Treatment

Real-time therapy response monitoring is greatly aided by liquid biopsies [6]. Clinicians can learn more about the progression of a disease and the effectiveness of a treatment by monitoring dynamic changes in circulating biomarkers, such as changes in CTC counts, cfDNA mutational profiles, or miRNA expression patterns [7]. By enabling timely modifications to treatment plans, this real-time monitoring improves patient care [8].

The selection of alternative medicines or combination methods is aided by liquid biopsies' capacity to detect evolving resistance mechanisms during treatment [9]. Furthermore, by starting therapeutic treatments on time, liquid biopsies' early diagnosis of treatment resistance slows the course of the disease and enhances patient outcomes [10].

Tracking the Development and Recurrence of Diseases

One potentially useful method for tracking the course of a disease and identifying recurrences of cancer is liquid biopsies [11]. Clinicians can monitor changes in tumour load, genetic mutations, and metastatic potential over time thanks to the dynamic nature of circulating biomarkers [12]. Prognostication and individualised treatment plans are made possible by the insights gained from the serial analysis of

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
***Article Received:** 20 May 2023 **Revised:** 28 July 2023 **Accepted:** 16 August 2023*

CTCs, cfDNA, EVs, and miRNAs into the dynamics of the illness [13].

Moreover, the use of liquid biopsies in post-treatment surveillance facilitates the early identification of recurrence or residual illness, frequently prior to the onset of clinical signs [14]. Timely action, such as commencing salvage medications or enrolling patients in clinical trials for innovative medicines, may improve outcomes when illness recurrence is promptly identified [15].

Decision-making in Treatment and Personalised Medicine

Personalised medicine in cancer is made possible by the clinical practice's use of biomarkers acquired from liquid biopsies [16]. Targeted therapy can be guided by the discovery of actionable mutations or molecular signatures obtained from the molecular characterisation of tumours using liquid biopsies [17]. Based on each patient's unique tumour profile, clinicians can customise treatment plans to maximise therapeutic results and reduce side effects [18].

Additionally, the discovery of predictive biomarkers for immunotherapy response is made easier by the study of circulating biomarkers, which helps in the patient selection process for immune checkpoint inhibitors [19]. Liquid biopsies aid in the improvement of therapy algorithms, enabling a more accurate and efficient method of managing cancer [20].

Section 3: Implementing Liquid Biopsies Presents Difficulties

Standardisation and Technical Difficulties

The technological difficulty of isolating and evaluating circulating biomarkers is one of the main obstacles to the widespread use of liquid biopsies [1]. Biomarkers, such as CTCs, cfDNA, EVs, and miRNAs, are varied and require specific extraction and detection techniques [2]. It is important to establish standard methods for sample collection, processing, and analysis to guarantee consistency and dependability among various labs and platforms [3].

Liquid biopsy tests' sensitivity and specificity also need to be optimised in order to identify uncommon mutations or low-abundance biomarkers among a backdrop of typical cell-derived biomolecules [4]. To provide standardised procedures and guarantee accuracy and comparability of outcomes, consensus criteria and proficiency testing are essential [5].

Variability in Sample Collection and Processing

The clinical use of liquid biopsies is severely hampered by the variation in sample collecting and processing techniques [6]. The number and integrity of circulating biomarkers can be affected by variables such sample handling procedures, storage conditions, and differences in blood collection tubes [7].

Standardisation of pre-analytical factors is essential to reduce variability and guarantee the dependability of liquid biopsy findings. Examples of these variables include the best blood collection tubes, storage temperatures, and processing schedules [8]. To further reduce possible biases caused during sample collection and processing, approved pre-analytical procedures and quality control methods must be developed [9].

Economicalness and Availability

One major obstacle to the broad use of liquid biopsy-based tests in standard clinical practice is their cost [10]. Accessibility may be restricted by the costs associated with specialised tools, chemicals, and advanced technology for biomarker identification, especially in environments with limited resources [11].

To improve accessibility and cost-effectiveness, initiatives are being made to simplify and optimise liquid biopsy workflows, lower assay expenses, and provide more accessible platforms [12]. The goal of collaborative efforts including academics, industry, and stakeholders in healthcare is to create assays that are affordable without sacrificing sensitivity and accuracy [13].

Analysis and Interpretation of Data

Converting molecular knowledge into therapeutically useful insights is difficult when dealing with sophisticated liquid biopsy data interpretation and analysis [14]. Acquiring advanced bioinformatics tools and analytical techniques is necessary for the integration of multi-omic data, such as transcriptomics, proteomics, and genomics [15].

The creation of user-friendly computational tools and the standardisation of data analysis pipelines are essential for facilitating data reporting and interpretation in a way that is clinically useful [16]. Furthermore, creating extensive reference libraries and databases for circulating biomarkers would facilitate the interpretation and comparison of findings across various patient groups [17].

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
***Article Received:** 20 May 2023 **Revised:** 28 July 2023 **Accepted:** 16 August 2023*

Ethics and Regulation Concerns

Clinical liquid biopsy application presents substantial hurdles, including navigating regulatory frameworks and ethical issues [18]. Tough clinical validation trials proving analytical validity, clinical value, and safety are necessary for regulatory bodies to validate and approve liquid biopsy tests [19].

In addition, ethical issues pertaining to patient permission, confidentiality, and the appropriate handling of delicate molecular data must be taken into account [20]. Building confidence and defending patient rights require policies and procedures that specify the moral application of data from liquid biopsies and guarantee patient privacy.

Section 4: Prospective Future Paths and Possible Effects

Technological and Methodological Developments

The development of technology and methods targeted at improving sensitivity, specificity, and scalability will play a significant role in the future of liquid biopsies in cancer [1]. The next generation of sequencing technologies, including digital PCR and next-generation sequencing (NGS), will allow for more accurate and thorough identification of circulating biomarkers [2].

In order to get a better understanding of tumour biology, single-cell analysis approaches have the potential to discover unusual subpopulations of circulating tumour cells or tumor-derived materials, as well as to unravel intra-tumoral heterogeneity [3]. Because these technical developments make it possible to identify even the smallest changes in the tumour landscape, liquid biopsies will become much more clinically useful.

Incorporation into Standard Practice and Clinical Trials

Therapeutic development and patient stratification are about to undergo a revolutionary shift with the introduction of biomarkers obtained from liquid biopsies into clinical trials [4]. In order to influence trial design and therapeutic methods, liquid biopsies provide the ability to dynamically monitor therapy response, discover resistance mechanisms, and forecast patient outcomes [5].

Moreover, the validation and integration of tests based on liquid biopsies into mainstream clinical practice might revolutionise cancer standard-of-care methods [6]. Personalised therapeutic treatments, disease progression monitoring, and treatment decision-making will be aided by the provision of real-time, non-invasive evaluations of tumour dynamics [7].

Personalised Health Care and Therapeutic Choices

Liquid biopsies' trajectory in cancer portends a move towards personalised medicine by allowing doctors to customise therapies according to each patient's unique molecular profile and illness features [8]. Precision oncology techniques will benefit from the identification of actionable mutations, predictive biomarkers, and resistance mechanisms using liquid biopsies [9].

Furthermore, real-time modifications to treatment plans are possible due to the dynamic nature of liquid biopsy analysis, which maximises therapeutic benefits and reduces side effects [10]. Better patient care will result from the integration of multi-omic data from liquid biopsies with clinical factors, which will open the door to more accurate prognostication and therapy stratification [11].

Finding New Targets and Biomarkers

Liquid biopsies remain a rich source of biomarkers, revealing new targets for prognostication and therapeutic intervention [12]. The range of clinically useful biomarkers will grow with the discovery of distinct biomarker signatures linked to various cancer kinds or stages [13].

Investigating non-coding RNAs, epigenetic changes, and functional proteomics in liquid biopsy samples may open up new therapeutic or immunotherapeutic treatment options [14]. These findings will increase our knowledge of tumour biology and open up new avenues for the development of creative treatment approaches.

Collaboration Efforts and Implementation Challenges

Liquid biopsies have a bright future, but solving the implementation's present issues is still crucial [15]. To expedite standardisation, verify tests, and provide recommendations for clinical usage, cooperation between researchers, physicians, industry partners, and regulatory agencies is crucial [16].

Moreover, it will take coordinated multidisciplinary efforts and strategic partnerships to overcome obstacles related to cost-effectiveness, accessibility, and data interpretation. Getting beyond these obstacles will be essential to realising liquid biopsies' full potential and implementing them into standard clinical procedures, which will ultimately transform the field of cancer detection and treatment.

International Journal on Recent and Innovation Trends in Computing and Communication
ISSN: 2321-8169 Volume: 11 Issue: 8
Article Received: *20 May 2023* ***Revised:*** *28 July 2023* ***Accepted:*** *16 August 2023*

Section 5: conclusion

Liquid Biopsies' Potential for Transformation

Liquid biopsies, which provide dynamic and non-invasive insights into the molecular landscape of disease, represent a fundamental paradigm change in oncology [1]. Their capacity to identify and examine circulating biomarkers, such as CTCs, cfDNA, EVs, and miRNAs, has revolutionised the ways in which cancer is diagnosed, tracked, and treated [2].

Liquid biopsies' non-invasiveness avoids the drawbacks of conventional tissue biopsies, allowing for repeated sample and real-time tracking of the course of a disease [3]. A paradigm shift in the management of cancer has resulted from this revolutionary potential, with a focus on timely, precise, and personalised therapies [4].

Clinical Significance Throughout the Cancer Spectrum

Liquid biopsies have proven to be remarkably useful in the clinical diagnosis, monitoring of therapy response, and tracking of disease progression across the whole cancer continuum [5]. Proactive treatments and improved patient outcomes are made possible by the capacity to identify minimum residual illness, evaluate therapy response in real-time, and predict disease recurrence [6].

Furthermore, the incorporation of biomarkers acquired from liquid biopsies into clinical decision-making procedures enables customised and focused treatments, maximising therapeutic outcome and reducing side effects [7]. Precision oncology is entering a new age thanks to the extensive and dynamic molecular insights that liquid biopsies give, which help in the development of personalised treatment methods [8].

Current Difficulties and Future Prospects

Although liquid biopsies have the potential to revolutionise medicine, there are still obstacles in the way of a smooth transition from laboratory to clinical practice [9]. Scientific communities, industrial partners, and regulatory agencies must work together to address technical challenges, standardisation concerns, financial difficulties, and obstacles to data interpretation [10].

Nevertheless, persistent progress in technology, techniques, and cooperative endeavours is well-positioned to surmount these obstacles and augment the therapeutic relevance of liquid biopsies [11]. Unlocking the full potential of liquid biopsies in cancer will need future initiatives that centre on improving methods, validating assays, integrating multi-omic data, and broadening the repertory of biomarkers [12].

Effect on Medical Care and Other Areas

Liquid biopsies have an influence on patient care, research, and healthcare economics in addition to the fields of diagnostics and treatments [13]. Liquid biopsies have the potential to improve patient outcomes, increase quality of life, and save healthcare costs related to managing late-stage diseases by enabling more accurate and early therapies [14].

Liquid biopsies also yield a plethora of molecular data that support research efforts by clarifying complex elements of tumour biology, therapeutic targets, and drug resistance mechanisms [15]. This information advances the field's quest for more precise and successful cancer treatments by fostering a greater understanding of cancer biology and aiding in the creation of innovative medicines [16].

References

1. Alix-Panabières, C., & Pantel, K. (2013). Circulating tumor cells: Liquid biopsy of cancer. Clinical Chemistry, 59(1), 110–118. [PubMed ID: 23144141]
2. Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., ... & Meropol, N. J. (2008). Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(19), 3213–3221. [PubMed ID: 18565886]
3. Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., ... & Rosenfeld, N. (2017). Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nature Reviews Cancer, 17(4), 223–238. [PubMed ID: 28233804]
4. Zhang, L., Riethdorf, S., Wu, G., Wang, T., Yang, K., Peng, G., ... & Pantel, K. (2012). Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clinical Cancer Research, 18(20), 5701–5710. [PubMed ID: 22896683]
5. Heitzer, E., Ulz, P., Geigl, J. B., & Speicher, M. R. (2015). Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies. Molecular Oncology, 10(3), 494–502. [PubMed ID: 26706639]
6. Yang, X., Zhuo, M., Ye, X., Bai, H., Wang, Z., Sun, Y., ... & Wang, J. (2017). Quantification of

mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget, 7(15), 20810–20824. [PubMed ID: 26919238]

7. Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., ... & Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 7(1), 1535750. [PubMed ID: 30637094]
8. Schwarzenbach, H., Hoon, D. S., & Pantel, K. (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer, 11(6), 426–437. [PubMed ID: 21562581]
9. Liu, X., Li, C., Li, J., Yu, T., Zhou, G., Cheng, J., ... & Cheng, X. (2016). Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Experimental and Therapeutic Medicine, 11(5), 2105–2110. [PubMed ID: 27168842]
10. Lippi, G., Mattiuzzi, C., & Favaloro, E. J. (2014). Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: Meta-analysis. International Journal of Cardiology, 171(3), 419–421. [PubMed ID: 24373948]
11. Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 14(9), 531–548. [PubMed ID: 28675160]
12. Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., ... & Diehn, M. (2016). Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 7, 11815. [PubMed ID: 27283993]
13. Pantel, K., & Alix-Panabières, C. (2019). Liquid biopsy in 2019: Circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nature Reviews Gastroenterology & Hepatology, 16(2), 71–72. [PubMed ID: 30622359]
14. Zuo, Z., Chen, S. S., Chandra, P. K., Galbincea, J. M., Soape, M., Doan, S., ... & Luthra, R. (2019). Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Modern Pathology, 32(10), 1439–1447. [PubMed ID: 31086337]
15. Diaz, L. A., Bardelli, A. (2014). Liquid biopsies: Genotyping circulating tumor DNA. Journal of Clinical Oncology, 32(6), 579–586. [PubMed ID: 24419122]
16. Yokoyama, K., Ishibashi, K., Kodama, M., Iwao-Koizumi, K., Kato, K., & Ando, T. (2016). Liquid biopsy for EGFR T790M mutation in lung cancer. Molecular Diagnosis & Therapy, 20(3), 209–213. [PubMed ID: 27170208]
17. Rolfo, C., Cardona, A. F., Cristofanilli, M., Paz-Ares, L., Diaz, M., Parrinello, G., ... & Russo, A. (2018). Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 131, 91–98. [PubMed ID: 30228006]
18. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., ... & Kinzler, K. W. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319), 1114–1117. [PubMed ID: 20981102]
19. Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., ... & Swanton, C. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545(7655), 446–451. [PubMed ID: 28445469]
20. Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., ... & Alizadeh, A. A. (2018). Integrating genomic features for non-invasive early lung cancer detection. Nature, 563(7732), 545–549. [PubMed ID: 30401858]